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Abstract
Background: Moderate-to-severe diarrhea (MSD) in the first 2 years of life can impair linear growth. We sought to
determine risk factors for linear growth faltering and to build a clinical prediction tool to identify children most
likely to experience growth faltering following an episode of MSD.
Methods: Using data from the Global Enteric Multicenter Study of children 0–23 months old presenting with MSD
in Africa and Asia, we performed log-binomial regression to determine clinical and sociodemographic factors
associated with severe linear growth faltering (loss of ≥ 0.5 length-for-age z-score [LAZ]). Linear regression was used
to estimate associations with ΔLAZ. A clinical prediction tool was developed using backward elimination of
potential variables, and Akaike Information Criterion to select the best fit model.
Results: Of the 5902 included children, mean age was 10 months and 43.2% were female. Over the 50–90-day
follow-up period, 24.2% of children had severe linear growth faltering and the mean ΔLAZ over follow-up was
− 0.17 (standard deviation [SD] 0.54). After adjustment for age, baseline LAZ, and site, several factors were
associated with decline in LAZ: young age, acute malnutrition, hospitalization at presentation, non-dysenteric
diarrhea, unimproved sanitation, lower wealth, fever, co-morbidity, or an IMCI danger sign. Compared to children
12–23 months old, those 0–6 months were more likely to experience severe linear growth faltering (adjusted
prevalence ratio [aPR] 1.97 [95% CI 1.70, 2.28]), as were children 6–12 months of age (aPR 1.72 [95% CI 1.51, 1.95]). A
prediction model that included age, wasting, stunting, presentation with fever, and presentation with an IMCI
danger sign had an area under the ROC (AUC) of 0.67 (95% CI 0.64, 0.69). Risk scores ranged from 0 to 37, and a
cut-off of 21 maximized sensitivity (60.7%) and specificity (63.5%).
Conclusion: Younger age, acute malnutrition, MSD severity, and sociodemographic factors were associated with
short-term linear growth deterioration following MSD. Data routinely obtained at MSD may be useful to predict
children at risk for growth deterioration who would benefit from interventions.
Keywords: Diarrheal diseases, Malnutrition, Stunting, Growth retardation, Nutritional deterioration, Diarrhea
sequelae, Clinical prediction
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Background
Chronic malnutrition is highly prevalent among children
under age 5 globally, with the greatest burden affecting
children in low- and middle-income countries (LMICs)
in Africa and Asia [1]. Stunting, defined as height- or
length-for-age (HAZ/LAZ) less than 2 standard devia-
tions below the population standard mean [2], is an indi-
cator of chronic malnutrition [3]. Fifteen percent of all
deaths and 21% of disability-adjusted-life-years in chil-
dren under 5 years have been attributed to stunting [4].
Stunting also has long-term consequences, including
impaired cognitive development, increased risk of non-
communicable disease in adulthood, and decreased eco-
nomic productivity [5].
Although the etiology of chronic malnutrition is multi-
faceted, an estimated 13.5% of global stunting prevalence
is attributable to diarrheal disease [6]. A meta-analysis of
longitudinal studies in 5 LMICs reported a child’s odds of
stunting at 24months of age increased by 16% with every
5% increase in incidence of diarrhea (odds ratio 1.16 [95%
confidence interval (95% CI) 1.07, 1.25]) [7]. In addition,
children in seven LMICs across Africa and Asia who expe-
rienced moderate-to-severe diarrhea (MSD) lost signifi-
cantly more height/length for age z-score (HAZ/LAZ) in
the 2–3months following the episode than age- and
village-matched controls [8].
Addressing linear growth faltering in children with
MSD may be an important step towards reducing stunt-
ing and its long-term consequences. This may be par-
ticularly true for those under 24 months of age, as this is
the critical time period in which most growth faltering
occurs [9] and during which interventions are likely to
be effective. However, it is unclear which groups of chil-
dren are at highest risk. In addition, few interventions
have been successful at mitigating the nutritional conse-
quences of diarrhea [10]. Identifying risk factors for
post-MSD linear growth faltering can inform which
groups of children should be prioritized for inclusion in
trials of potential interventions, and, once an effective
intervention has been identified, to optimize the effect-
iveness of intervention delivery within programs by tar-
geting children at high risk of growth faltering.
Using data from children under 24 months old with
MSD enrolled in a previous large diarrhea etiology study
(the Global Enteric Multicenter Study, or GEMS), we
sought to identify determinants of linear growth faltering
in the 60–90 days following presentation with MSD. We
evaluated the frequency and severity of linear growth fal-
tering in this population and identified the clinical, host,
and socioeconomic factors associated with faltering in
linear growth during the short-term follow-up period.
We also developed and validated a predictive model and
risk scoring tool for estimating an individual child’s risk
of short-term growth faltering following MSD.
Methods
Study setting and populations
GEMS [8] was a large case-control study of the inci-
dence, etiology, and clinical consequences of MSD
among children 0–59 months of age conducted between
2007 and 2011 in Bangladesh, India, Pakistan, Kenya,
Mali, Mozambique, and The Gambia. Here we describe
a case-only analysis, using data on MSD cases in GEMS,
defined as children seeking care at study health facilities
for an episode of new (onset after ≥ 7 diarrhea-free days)
and acute diarrhea (≥ 3 abnormally loose stools within
the previous 24 h with an onset within the previous 7
days) with at least one of the following characteristics:
dehydration (presence of sunken eyes, loss of skin tur-
gor, intravenous hydration administered or prescribed),
dysentery (presence of visible blood in diarrhea), or clin-
ical decision to admit to hospital. Children presenting
with prolonged (> 7 days’ duration) and persistent (> 14
days’ duration) diarrhea were excluded. GEMS included
a single follow-up visit predefined at 60 days (with an ac-
ceptable range of 50–90 days) following enrollment.
Study clinicians performed physical exams and con-
ducted interviews with caregivers at enrollment and at
follow-up to ascertain clinical, anthropometric, and
sociodemographic factors. Children’s weight was mea-
sured at enrollment (MSD presentation). Child’s length
and middle-upper arm circumference (MUAC) were
measured 3 times at each visit, and median measures
used in the analysis. Study clinicians also abstracted data
from medical records if the child was hospitalized at en-
rollment. The clinical and epidemiological methods used
in GEMS, including the standardized procedures for
obtaining anthropometric measurements, have been de-
scribed in detail [11].
This post hoc analysis used the enrollment and
follow-up data of the MSD cases enrolled in GEMS,
restricting to children under 24 months of age. Chil-
dren were therefore included in this analysis if they
were an MSD case, were under 24 months of age,
and had both LAZ measurements available at enroll-
ment and follow-up; therefore, children who died or
were lost to follow-up were excluded. We also ex-
cluded children with implausible length/LAZ values
(LAZ > 6 or < − 6 and change in (Δ) LAZ > 3; a length
gain of > 8 cm for follow-up periods 49–60 days and
> 10 cm for periods 61–91 days among infants ≤ 6
months, a length gain of > 4 cm for follow-up pe-
riods 49–60 days and > 6 cm for periods 61–91 days
among children > 6 months, or length values that
were > 1.5 cm lower at follow-up than at enrollment).
Because standards for MUAC are not available for
children under 6 months of age, only MUAC mea-
surements for children over 6 months of age were
included in the analysis.
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Variables and definitions
Outcomes
We defined faltering in linear growth using change in
length-for-age z-score (ΔLAZ) between enrollment and
follow-up. Linear growth faltering was defined in two
ways: (1) as a continuous variable (ΔLAZ) with ΔLAZ< 0
being considered a loss and (2) as a binary variable, se-
vere linear growth faltering, defined as loss of 0.5 LAZ
or more (ΔLAZ ≥ − 0.5).
Risk factors
Risk factors examined in this analysis included clinical and
sociodemographic factors. Factors included age (per date
of birth reported by the primary caretaker and verified by
the child’s health card), sex, admission to hospital at pres-
entation, presentation with fever (axillary temperature
> 37.5 F), co-morbidities per final diagnosis indicated on
medical records, LAZ at presentation calculated according
to WHO standards [2], wasting (weight-for-length z-score
[WLZ] < − 2 using WHO standards, using post-
rehydration weight), dysentery (visible blood in stool
observed by caregiver or health care provider at presenta-
tion), stunting (LAZ < − 2 using WHO standards), and
duration of diarrhea (caregiver reported number of days
the diarrhea has lasted at presentation). Anthropometric
z-scores were calculated using WHO Stata macro code
[12]. Duration of diarrhea was ascertained by summing
the duration of diarrhea during the 7 days prior to enroll-
ment (children with diarrhea lasting longer than 7 days
were excluded from participation) plus duration of diar-
rhea during the 14 days after enrollment. Diarrhea dur-
ation for the 14 days following enrollment was ascertained
using a memory aid suitable for groups of all literacy
levels, which the caregiver returned at the follow-up visit,
as depicted elsewhere [11]. Cessation of the enrollment
episode was defined as two consecutive days in which
diarrhea was not reported. Diarrhea was categorized as
acute diarrhea (defined above), prolonged (> 7–13 days
duration), or persistent (≥ 14 days duration). Sociodemo-
graphic characteristics were evaluated at enrollment and
included access to improved water (caregiver report of the
following: main source of drinking water for the house-
hold is piped into house or yard, public tap, tubewell, cov-
ered well, protected spring, rainwater, or borehole; is
accessible within 15min or less, roundtrip; and is available
daily), access to improved defecation facility (caregiver
report of access to the following: flush toilet, ventilated
improved pit latrine with or without water seal, or pour
flush toilet not shared with other households), caregiver
handwashing (caregiver report of handwashing before eat-
ing, before handling child’s food, after defecation, or after
disposing of child’s feces), and wealth quintile (quintile of
a wealth effects score calculated from asset ownership in-
formation reported by caregiver at enrollment [13]).
Caretakers were shown pictures to aid in accurate identifi-
cation of water and sanitation facilities.
Data analysis
Risk factor model
Univariate and multivariable relative risk regression
models specifying a binomial distribution (or Poisson
distribution if model failed to converge [14]) with robust
standard errors were used to estimate relative risks of se-
vere linear growth faltering and 95% confidence intervals
(95% CIs). Univariate and multivariable linear regression
models with robust standard errors were used to esti-
mate continuous ΔLAZ and 95% CIs associated with the
exposure variables of interest. Multivariable models were
adjusted a priori for age, site, duration of follow-up, and
LAZ at enrollment.
As children who were missing LAZ measurements at
one or both of the study visits were excluded, we re-
peated the analysis of risk factors using imputed LAZ
values for children in whom follow-up LAZ was miss-
ing due to loss to follow-up or death [15]. We con-
ducted multiple imputation for monotone missing data,
which assumes missingness at random conditional on
observed characteristics. Imputation models included
linear regression to impute ΔLAZ and Poisson regres-
sion to impute severe linear growth faltering. Variables
were selected for inclusion in the imputation if they
were associated with missingness, per χ2 tests for cat-
egorical variables and t tests for continuous variables.
Diagnostics of the imputation models included examin-
ing imputed values for reasonableness (whether the
values were plausible and scientifically sensible given
the covariates in the model) and comparing distribu-
tions of imputed vs observed values. All analyses were
conducted in Stata 14.
Clinical prediction tool
In addition to a risk factor model, a clinical prediction
model was developed to identify the combinations of
factors that best predicted a child’s risk of severe linear
growth faltering in the 50–90 days following MSD. We
included only the characteristics in Table 1 that are eas-
ily collectible in a clinical setting in the prediction
model. The data were randomly divided into separate
derivation and validation datasets of equal size, and
t tests or χ2 tests used to identify differences in baseline
characteristics between the datasets. A backward elimin-
ation approach [16, 17] was used to develop the model,
in which all candidate variables are included and elimi-
nated based on statistical significance (p ≤ 0.1). We used
the Akaike Information Criterion (AIC), a measure of
model fit that penalizes larger models and thus attempts
to reduce overfitting, to select the best fit model. We
translated the best-fit model into a practical risk scoring
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tool by assigning values for each predictor based on the
beta-coefficients from the model as described elsewhere
[18]. The sum of risk scores for each parameter was the
total risk score for each child. To validate the model, the
risk score was applied to the validation cohort, and AUC
performance and Brier score were compared with the
derivation cohort.
We assessed the ability of the risk score to discrimin-
ate between children with and without severe linear
growth faltering, with risk score as the sole predictor,
Table 1 Baseline characteristics of children with MSD included in this GEMS analysis
n (%) or median (interquartile range)
Sociodemographic characteristics
Age, months 11 (7–16)
0–6 months 1077 (17.4%)
> 6–12 months 2361 (38.1%)
> 12–23months 2765 (44.6%)
Site








Access to improved water 2824 (45.5%)
Access to improved sanitationa 1153 (18.6%)
Wealth index score [13] − 0.08 (− 0.71, 0.59)
Clinical characteristics at presentation
Stunting 1478 (23.8%)
Wasting 1357 (21.9%)
Severe wastingb 470 (7.6%)
MUAC < 12.5 cm among 5126 children 6–23 months 863 (16.8% of 5126 children)
Fever 1788 (30.3%)




Hospitalized at presentation 1229 (19.8%)
Dysentery at presentationc 1352 (21.8%)
≥ 1 IMCI general danger sign 3661 (59.0%)




Other invasive bacterial infection 82 (1.3%)
Upper respiratory tract infection 8 (0.1%)
aFlush toilet, ventilated improved pit latrine with or without water seal, or pour flush toilet not shared with other households
bSevere wasting defined as weight-for-length z-score < − 3
cVisible blood in stool observed by study staff or reported by caregiver at presentation; discharge diagnosis of dysentery per managing clinician upon leaving the
healthcare facility; or observed in stool sample by laboratory staff
dPer discharge diagnoses documented on medical records
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using receiver operating characteristic (ROC) analysis to
calculate the area under the curve (AUC) [19]. We also
estimated Brier scores to quantify the difference between
the predicted and actual outcomes; useful prediction
models have Brier scores < 0.25 [19]. Risk scores were
dichotomized into the most predictive categories using
the cut-point identified in ROC analysis, which opti-
mizes sensitivity and specificity. Positive and negative
predictive values (PPV, NPV) were also calculated.
Results
Among the 9439 children with MSD who were enrolled
in the GEMS study, 2205 children aged ≥ 24months and
1031 children with a missing or implausible LAZ value
were excluded. This resulted in 6203 surviving children
under 24 months of age included in the analysis (Fig. 1).
Median age of included children was 11months (inter-
quartile range 7–16) and 43.2% were female (Table 1).
Distribution across the 7 sites was similar to that in the
parent study: 705 (11.4%) in The Gambia, 1172 (18.9%)
in Mali, 410 (6.6%) in Mozambique, 961 (15.5%) in
Kenya, 1195 (19.3%) in India, 993 (16.0%) in Bangladesh,
and 767 (12.4%) in Pakistan. Approximately 22% (n =
1352) of children presented with dysentery, 94.4% of
whom were given or prescribed an antibiotic in the
health facility (whereas 75.4% of children without dysen-
tery were given an antibiotic). Thirty percent presented
with fever and 19.8% were hospitalized at presentation.
Approximately, one in four children presenting with
MSD were stunted at presentation and one in five were
wasted. Approximately 43.2% (n = 2681) of these chil-
dren under 24 months of age experienced a subsequent
diarrhea episode during the follow-up period, per care-
giver report at the follow-up visit.
Mean ΔLAZ between enrollment and follow-up was
− 0.25 (standard deviation [SD] 0.50). Median ΔLAZ
was − 0.24 (interquartile range − 0.55, 0.05), and
28.6% developed severe linear growth faltering (loss of
≥ 0.5 LAZ) during the 90-day follow-up period. Not-
ably, 82.9% of these children who lost ≥ 0.5 LAZ
during follow-up were not stunted at MSD presenta-
tion, and 73.4% of these were not wasted. Children
whose caregivers reported they experienced a subse-
quent diarrhea episode during follow-up lost slightly
more LAZ (ΔLAZ = − 0.27) than those who did not
(ΔLAZ − 0.23) (p value from t test = 0.01).
Risk factor analysis
ΔLAZ
Age and nutritional status at MSD presentation, but not
sex, were associated with ΔLAZ. Children > 6–12
months old lost approximately 0.07 more LAZ than chil-
dren > 12–23 months (aβ − 0.10 [95% CI − 0.10, − 0.04])
adjusting for duration of follow-up, baseline LAZ, and
site, and ΔLAZ was not statistically significantly different
between children 0–6 months and those > 12–23months
(Table 2 and Fig. 2). Figure 2a depicts the pattern of
ΔLAZ by age, demonstrating that the magnitude of LAZ
loss decreased with each month gain in age. Children
with higher baseline LAZ values experienced the greatest
loss in LAZ (Fig. 2c), in an inverse relationship pattern;
magnitude of LAZ loss decreased consistently with each
unit increase in LAZ (aβ − 0.08 [95% CI − 0.09, − 0.07]).
Children stunted at MSD presentation gained LAZ com-
pared to their non-stunted counterparts (aβ 0.16 [95%
CI 0.13, 0.19]) whereas wasted children lost an average
of 0.21 LAZ more than children without wasting (95%
CI − 0.24, − 0.18). Among children over 6 months of age,
children with MUAC < 12.5 cm lost 0.12 more LAZ
(95% CI − 0.15, − 0.08) than those with MUAC of ≥ 12.5
cm, after accounting for age, site, duration of follow-up,
and baseline LAZ. Children who had a final diagnosis of
malnutrition per discharge medical records lost 0.19
more LAZ than those who did not (95% CI − 0.24,
− 0.13). Males’ ΔLAZ was similar to that of females (aβ
0.02 [95% CI − 0.0003, 0.05]).
Several clinical factors at MSD presentation were as-
sociated with ΔLAZ. Children who were hospitalized at
enrollment lost 0.11 more LAZ than those who were
not (95% CI − 0.14, − 0.07) and those who presented
Fig. 1 Flowchart of included subjects
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with fever lost 0.09 more LAZ (95% CI − 0.09, − 0.06)
in adjusted analysis. Children presenting with at least
one Integrated Management of Childhood Illness
(IMCI) danger sign lost more LAZ than those who had
none (aβ − 0.05 [95% CI − 0.08, − 0.02]). Presentation
with any co-morbidity was associated with losing more
LAZ (aβ − 0.09 [95% CI − 0.11, − 0.06]), but this associ-
ation was likely driven by one specific co-morbidity:
among the co-morbidities documented in medical
records, only a discharge diagnosis of malnutrition
was associated with loss of LAZ in the adjusted
analysis. Compared to children with non-dysenteric
MSD, those presenting with dysentery lost less LAZ
(aβ 0.07 [95% CI 0.07, 0.11]). Prolonged or persistent
MSD (using caregiver-recalled duration of diarrhea at
follow-up) was also not associated with linear growth
faltering.
In addition to clinical factors, several baseline socio-
demographic factors were also protective against loss
of LAZ. Children whose caregivers reported access to
an improved defecation facility lost substantially less
LAZ than those without access to this level of
sanitation (aβ 0.07 [95% CI 0.03, 0.11]) though access
to improved water sources were not significantly asso-
ciated. In addition, children in the highest wealth
quintile lost less LAZ than those in the lowest quin-
tile (aβ 0.08 [95% CI 0.04, 0.12]).
Using multiple imputation resulted in an additional
854 children being added to the dataset, resulting in
7057 included in the analysis with imputed outcomes.
An additional file presents distribution of imputed ver-
sus observed outcomes (Additional file 1: Figure S1), as
well as baseline characteristics between children with
imputed versus observed outcomes (Additional file 1:
Table S1). Factors associated with ΔLAZ calculated
using imputed values were similar to the complete-case
analysis (Additional file 1: Table S2), with no substan-
tial differences in effect size or statistical significance.
Severe linear growth faltering (loss ≥ 0.5 LAZ)
Prevalence of severe linear growth faltering by age and
nutritional status at presentation followed a similar pat-
tern to that of ΔLAZ (Table 2 and Fig. 2c/d); children
0–6 months of age were more likely to experience
Fig. 2 a–d Linear growth faltering following an episode of moderate-to-severe diarrhea by age and baseline LAZ
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severe linear growth faltering than children > 12–23
months (aPR 1.41 [95% CI 1.22, 1.51]). We also depict
the pattern of prevalence of severe linear growth falter-
ing by interactions between age and baseline LAZ
(Fig. 3). Unlike our results for ΔLAZ, female children
were 9% less likely to experience severe linear growth
faltering than males (aPR 0.91 [95% CI 0.83, 1.00]).
Hospitalization, fever, and at least one IMCI danger
sign were significant risk factors for severe linear
growth faltering, as they were for ΔLAZ. Non-
dysenteric MSD did not emerge as a statistically signifi-
cant risk factor for severe linear growth faltering (aPR
0.88 [95% CI 0.75, 1.02]), but the prevalence ratio did
approach statistical significance (p value = 0.09). Unlike
our results for ΔLAZ, the socio-demographic factors
examined (improved water source or defecation facility,
and wealth quintile) were not statistically significantly
associated with severe linear growth faltering in our
analyses.
Results for the analysis including imputed values were
similar (Additional file 1: Table S2).
Prediction model results
In the derivation dataset of 3101 children, there were
894 who experienced severe linear growth faltering
(28.8%). The validation cohort also consisted of 3102
children, of whom 882 (28.4%) experienced severe linear
growth faltering. Demographic and clinical characteris-
tics were similar between the derivation and validation
datasets (Table 3).
The final prediction model included age, sex, stunting
at enrollment, wasting at enrollment, presentation with
fever, presentation with at least 1 IMCI danger sign,
presentation with any comorbidity, and admission to
hospital at enrollment. These factors were used to create
a risk score for severe linear growth faltering each child
(Fig. 4). In the overall cohort, risk scores ranged from 0
to 55, and the median risk score was 27 (interquartile
range 20–32) (Fig. 5). Mean variance inflation factor was
1.9. Model fit was similar in the derivation and valid-
ation datasets (AUC 0.73 (95% CI 0.71, 0.74); 0.73 (95%
CI 0.72, 0.74), respectively) (Fig. 6). In the derivation
dataset, a cutoff of 27 optimized both sensitivity and
specificity at 63.2% and 67.2%, respectively (Table 4). In
the validation dataset, the sensitivity, specificity, PPV,
and NPV of the cutoff point of 27 in the validation data-
set were 60.6%, 69.9%, 44.7%, and 81.6%, respectively.
Also in the validation dataset, the risk score identified
children most likely to severely growth falter better than
any individual predictive factor: age (AUC = 0.31 [95%
CI 0.30, 0.33]), sex (AUC = 0.49 [95% CI 0.47, 0.50]),
stunting (AUC = 0.44 [95% CI 0.43, 0.45]), wasting
(AUC = 0.53 [95% CI 0.52, 0.54]), presentation with fever
(AUC = 0.55 [95% CI 0.53, 0.56]), presentation with at
least 1 IMCI danger sign (AUC = 0.57 [95% CI 0.55,
0.58]), presentation with any comorbidity (AUC = 0.53
[95% CI 0.47, 0.50]), and hospitalization at presentation
(AUC = 0.55 [95% CI 0.54, 0.56]).
Discussion
In this post hoc analysis of children with MSD enrolled
in the GEMS study, we found that over one-fifth of chil-
dren under 24 months had linear growth faltering at ~
60-days following the MSD episode. We identified sev-
eral risk factors for linear growth faltering, including
age, fever, general IMCI danger sign, and nutritional sta-
tus. We found that some of these factors yielded reason-
able predictive value to identify children likely to
experience severe linear growth faltering following MSD.
We found that most children who experienced linear
growth faltering were not stunted at MSD presentation.
Stunting status at diarrhea presentation may not identify
all children who are at risk for linear growth declines
following an episode of MSD. Using these other clinical
factors to predict linear growth faltering may result in
earlier and more complete identification of children who
are on a trajectory of linear growth declines, comparing
to using only stunting status at diarrhea presentation to
predict post-diarrhea growth declines and thus may be
useful for targeting interventions to prevent stunting.
Patterns of linear growth faltering followed patterns
determined by age and baseline LAZ. The older the
child, or the lower the LAZ value at enrollment, the
lower the probability that the child with lose LAZ over
the ensuing 2–3 months. Growth in early life is rapid
and decreases as the child ages [20, 21]. Correspond-
ingly, risks of linear growth faltering decrease as children
age, with the highest risk occurring before 12 months.
Our findings are consistent with previous work noting
the substantial losses of LAZ in early life [9] and suggest
that interventions may confer the most benefit within
Fig. 3 Risk of linear growth faltering in terms of interactions
between age and baseline LAZ
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this critical period. This growth pattern also underscores
methodological considerations for analyses of linear
growth faltering. Children in the youngest age groups
have the highest growth velocity and therefore have the
greatest opportunity to lose or gain LAZ. Growth falter-
ing in older children may have different underlying eti-
ologies and health implications than that occurring in
infancy, and so we have restricted the analysis to





n (%) or median (interquartile range) n (%) or median (interquartile range)
Sociodemographic characteristics
Age, months 11 (7–16) 11 (7–16)
0–6 months 559 (18.0%) 518 (16.7%)
> 6–12 months 1192 (38.4%) 1169 (37.7%)
> 12–23months 1350 (43.5%) 1415 (45.6%)
Site
The Gambia 346 (11.2%) 359 (11.6%)
Mali 609 (19.6%) 563 (18.1%)
Mozambique 193 (6.2%) 217 (7.0%)
Kenya 476 (15.3%) 485 (15.6%)
India 625 (20.2%) 570 (18.4%)
Bangladesh 493 (15.9%) 500 (16.1%)
Pakistan 359 (11.6%) 408 (13.2%)
Female 1358 (43.8%) 1323 (42.6%)
Access to improved water 1420 (45.8%) 1404 (45.3%)
Access to improved sanitationa 559 (18.0%) 594 (19.1%)
Wealth index [13] − 0.08 (− 0.71, 0.59) − 0.08 (− 0.72, 0.58)
Clinical characteristics at presentation
Stunting 715 (23.1%) 763 (24.6%)
Wasting 671 (21.6%) 686 (22.1%)
Severe acute malnutrition 227 (7.3%) 243 (7.9%)
MUAC < 12.5 cm among 6–23months 421 (16.6% of 2542) 442 (17.2% of 2542)
Fever 886 (30.0%) 902 (30.5%)
Current breastfeeding < 6months
Exclusive 220 (29.4% of 749) 219 (31.0% of 707)
Partial 498 (66.5% of 749) 453 (64.1% of 707)
None 31 (4.1% of 749) 35 (5.0% of 707)
Hospitalized at presentation 605 (19.5%) 624 (20.1%)
Dysentery at presentationb 681 (22.0%) 671 (21.6%)
≥ 1 IMCI general danger sign 1808 (58.3%) 1853 (59.7%)
Presented with at least 1 co-morbidityc 1027 (33.1%) 1049 (33.8%)
Pneumonia 2880 (92.9%) 2903 (93.6%)
Malaria 221 (7.1%) 199 (6.4%)
Malnutrition 741 (23.9%) 769 (24.8%)
Other invasive bacterial infection 161 (5.2%) 188 (6.1%)
Upper respiratory tract infection 47 (1.5%) 35 (1.1%)
aFlush toilet, ventilated improved pit latrine with or without water seal, or pour flush toilet not shared with other households
bVisible blood in stool observed by study staff or reported by caregiver at presentation; discharge diagnosis of dysentery per managing clinician upon leaving the
healthcare facility; or observed in stool sample by laboratory staff
cPer discharge diagnoses documented on medical records
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children under 24 months of age and controlled for age
and baseline LAZ in the analysis. Challenges in ascer-
taining and interpreting losses in linear growth by age
group highlight the need for research to assess the clin-
ical relevance of different magnitudes of loss in LAZ by
different age groups.
Similar to the patterns of LAZ loss by age, children
with LAZ values that are already low (below 0) were less
likely to lose more LAZ. We have described how losses
in LAZ increase consistently with higher LAZ, consistent
with patterns observed elsewhere [22]. While our results
suggest stunting status or low LAZ values may not iden-
tify children who are at risk for further linear growth de-
terioration, children who are already stunted are at high
risk of the health and cognitive detriments associated
with chronic malnutrition [5]. Whether health conse-
quences of loss in LAZ are differential by stunting status
remain unclear. A modest loss in LAZ may prove to
have more health consequences in already stunted chil-
dren than a loss of greater magnitude in non-stunted
children at diarrhea presentation.
We identified host, clinical, and environmental charac-
teristics that were significantly associated with short-
term linear growth faltering. Acute malnutrition
(measured either by MUAC or WLZ) was significantly
associated with subsequent growth faltering. This could
also reflect dehydration status, and this finding may re-
flect that the more dehydrated children had more severe
intestinal injury and absorptive capacity, and thus more
likely to experience linear growth faltering. Ponderal
growth has previously been found to be associated with
linear growth. A longitudinal analysis of birth cohorts
from the USA, Ghana, and Honduras reported that
WLZ was positively correlated with length gain [23], as
did a cohort study of Jamaican 9–24-month-old stunted
children [24]. Additionally, a study in the West Indies
reported that severely malnourished children needed to
attain ≥ 85% WLZ before they began to gain LAZ [25].
These studies suggest ponderal growth may precede lin-
ear growth, as weight loss reflects a lack of available nu-
trients needed to sustain linear growth. It is also possible
the higher risks of severe linear growth faltering we ob-
served in acutely malnourished children may be due to
higher rates of subsequent diarrhea episodes during the
Fig. 4 A risk scoring tool for predicting risk of linear growth faltering
among children presenting with MSD
Fig. 5 Distribution of risk scores among all children with complete outcome data (n = 6203)
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follow-up period. Previous research has reported higher
incidence of diarrhea in acutely malnourished children
[26, 27], though we did not have data on diarrhea be-
yond 14 days of follow-up to examine this hypothesis.
Acutely malnourished children presenting with MSD
may thus be an easily identifiable population who may
benefit from nutritional interventions that protect
against linear growth faltering.
Presentation with fever was associated with linear
growth faltering as has been shown previously [28].
Fever may be a sign of more severe intestinal inflam-
mation and injury, as is often seen in bacterial diar-
rhea, which may be associated with linear growth
faltering. This is supported by the finding that children
with MSD who were hospitalized at presentation were
at higher risk of linear growth faltering than those who
were not. Finally, the presence of any IMCI danger
sign at MSD presentation was also associated with a
loss of more LAZ. Studies have demonstrated the po-
tential of IMCI programs for improving quality of care
and child survival [29–31]. However, a Cochrane re-
view of the effectiveness of IMCI programs reported
little to no benefit on stunting or wasting [30] which
could reflect the lack of effective interventions for
improving nutritional status upon identification of
high-risk children.
In our analysis, children presenting with dysentery had
lower risks of linear growth faltering than those with
non-dysenteric MSD. This finding was unexpected and
differs from that of other studies that found dysentery,
or specific pathogens known to cause dysentery, to be
associated with risk for linear growth faltering [32–34].
Our detection of a reduced risk associated with dysen-
tery may be related to clinical management. WHO
guidelines recommend antibiotics for dysentery [35], and
in our data, children presenting with dysentery were
more likely to receive an antibiotic than those without.
It is unclear whether antibiotic management of MSD al-
ters growth [36]; some research has reported growth-
promoting effects of antibiotic treatment on length and
weight in children in LMICs [37, 38]. Clinical trial data
will be needed for evaluating the effectiveness of anti-
biotic management of MSD for protecting against subse-
quent linear growth faltering.
Fig. 6 ROC curve of predicted risks of severe linear growth faltering using risk scores in the derivation cohort
Table 4 Sensitivity, specificity, and predictive values of risk score at different cut-points in the derivation cohort
Risk score cut-point
≥ 11 ≥ 20 ≥ 27 ≥ 32 ≥ 40
No. of children (% of total [6203]) 5654 (91.2%) 4567 (73.4%) 3015 (48.6%) 1632 (26.3%) 324 (5.2%)
Sensitivity 96.7% 85.0% 63.2% 38.5% 7.9%
Specificity 27.3% 47.0% 67.2% 84.3% 96.8%
Positive predictive value 34.6% 38.9% 43.3% 49.3% 49.9%
Negative predictive value 90.6% 86.6% 81.2% 77.0% 72.4%
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We found that children in lower wealth quintiles had
the highest rates of linear growth faltering. Poverty is a
well-established underlying cause of childhood stunt-
ing. There are large disparities in stunting rates by
wealth quintile within LMICs, with child stunting rates
in lowest wealth quintiles as much as 13 times higher
than in the highest [39]. Socioeconomic factors are the
most consistently identified correlates of stunting [40],
and it has been estimated that every 10% increase in
national gross domestic production per person would
result in a 6% decrease in stunting prevalence [41]. Eco-
nomic development may be influential in protecting
children with MSD against linear growth faltering [42].
We found that children in households without access
to improved defecation facilities experienced greater
losses in LAZ, though results were not consistent for
both outcomes and for our analyses of water source.
Greater exposure to environmental pathogens may
place children at higher risk of linear growth faltering,
as pathogen-specific diarrhea [33, 34] and asymptom-
atic pathogen carriage [43–45] have been found to be
associated with linear growth faltering. Unimproved
WASH may also contribute to environmental enteric
dysfunction (EED), which is strongly associated with
linear growth faltering and thought to play a central
role in stunting [46, 47]. However, WASH interventions
have not yielded consistent benefits. While a review of
stunting in 137 LMICs using Global Burden of Disease
data reported unimproved sanitation to be a leading
cause of stunting [6], a Cochrane review reported only
modest benefits of WASH on child length but limited
availability and quality of evidence [48]. Large clinical
trials of WASH interventions did not detect a benefit
on child growth [49–51].
When considering which risk factors best predicted
likelihood of severe linear growth faltering, age, stunt-
ing, wasting, fever, and presence of any IMCI danger
sign emerged as the most important. The predictive
ability of the model was fair to moderate and could
benefit from further research to improve the predict-
ive ability of the model, perhaps by including data
not available in GEMS, such as birth weight or HIV
status information. External validation would further
improve the model. The risk score model performed
better than any individual predictive factor, suggesting
that the combination of these factors is more useful
for identifying children at risk of severe linear growth
faltering than any of these variables individually. We
identified the risk score cut-point that maximizes sen-
sitivity and specificity, but the cut-point used in prac-
tice should be weighed against the costs or negative
consequences of potential interventions. This predict-
ive model uses only easily collected clinical data rou-
tinely documented at diarrhea presentation, and such
a risk score could be useful for identifying children at
highest risk for inclusion in trials of interventions to
reduce linear growth faltering and ultimately may
prove useful in determining how to best apply suc-
cessful interventions once benefit is demonstrated, by
identifying high-risk children who stand to benefit
from such an intervention or be monitored more
closely following MSD.
There have been few studies to our knowledge that
identify risk factors of linear growth faltering in children
following an episode of MSD. Our study contributes
data on this important topic, using a large, multi-
country cohort with a rigorous study design and data
collection practices. There are several limitations to our
analysis as well. Data on birth size, HIV status, and pre-
vious and subsequent diarrhea episodes were not avail-
able in the parent study, which may be relevant to this
secondary analysis. Our analysis assessed short-term ef-
fects (2–3 months) only. It has been reported that catch-
up growth is possible following a diarrhea episode if no
subsequent diarrhea episodes are experienced [52], and
it is possible that some of the growth deficits we ob-
served were transient. The risk and predictive factors we
have identified for short-term losses in LAZ may or may
not be the same factors associated with longer term
growth declines. However, we found that a substantial
proportion of these children presenting with MSD expe-
rienced a repeated diarrhea episode in the subsequent
50–90 days, and this additional growth insult may have
precluded catch-up growth for this subset, who may
have continued on a linear growth decline. This short-
term period also represents a very vulnerable period, as
children’s risk of death was more than 8-fold in this
period following a MSD episode compared to healthy
controls [8]. Longer follow-up studies will be important
for assessing sustained linear growth deficits associated
with diarrhea, as well as other health outcomes associ-
ated with linear growth faltering at different ages. The
cut-off of 0.5 LAZ for our definition of severe linear
growth faltering is arbitrary, and the clinical implications
of this magnitude of loss are unclear. Additionally, all
definitions used implicitly assume the impact of LAZ
loss is the same, irrespective of age or enrollment LAZ.
We adjusted for age and LAZ at baseline in our analysis,
but difficulties remain with interpreting the health detri-
ments of these outcomes.
Conclusion
Children presenting with MSD that are acutely malnour-
ished (or more dehydrated), under 12 months of age,
presenting with more severe disease (as indicated by
hospitalization, presence of fever, or IMCI danger signs),
and those living with limited access to improved sanita-
tion may be at higher risk of linear growth faltering
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following MSD. To identify children for inclusion in fur-
ther trials and to guide clinical decision-making for close
monitoring of high-risk children or targeting an inter-
vention once an effective intervention has been identi-
fied, age, nutritional status, and signs of disease severity
may be useful to identify children at highest risk.
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